(Q43268245)

17 November 2017

title

Intravitreal triamcinolone acetonide vs bevacizumab for treatment of macular oedema secondary to branch retinal vein occlusion (English)

1 reference

17 November 2017

1 reference

K-C Cheng

1

1 reference

17 November 2017

W-C Wu

series ordinal

2

1 reference

17 November 2017

K-J Chen

series ordinal

3

1 reference

17 November 2017

publication date

2 October 2009

1 reference

17 November 2017

1 reference

17 November 2017

volume

23

1 reference

17 November 2017

issue

11

1 reference

17 November 2017

page(s)

2023-2033

1 reference

Prevalence and associations of retinal vein occlusion in Australia. The Blue Mountains Eye Study

17 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2009.230

Ischemic macular edema. Recognition and favorable natural history in branch vein occlusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2009.230

Modified grid laser photocoagulation for diabetic macular edema. The effect on the central visual field

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2009.230

Progressive Enlargement of Laser Scars Following Grid Laser Photocoagulation for Diffuse Diabetic Macular Edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2009.230

Choroidal Neovascularization after Laser Photocoagulation for Diabetic Macular Edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2009.230

Pathogenesis of macular edema with branch retinal vein occlusion and intraocular levels of vascular endothelial growth factor and interleukin-6.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2009.230

Argon laser photocoagulation for macular edema in branch vein occlusion. The Branch Vein Occlusion Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2009.230

7 January 2021

Retinal vein occlusion. Clinical and experimental observations

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2009.230

7 January 2021

Retinal tributary vein occlusion. History and management by photocoagulation

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2009.230

7 January 2021

Pathophysiology and hemodynamics of branch retinal vein occlusion

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2009.230

7 January 2021

Macular edema secondary to occlusion of the retinal veins

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2009.230

7 January 2021

Laser-induced chorioretinal venous anastomosis for nonischemic central retinal vein occlusion: evaluation of the complications and their risk factors

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2009.230

7 January 2021

Submacular fibrosis after photocoagulation for diabetic macular edema

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2009.230

7 January 2021

Automatic static threshold perimetry is useful for estimating the effects of laser photocoagulation on diabetic maculopathy

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2009.230

7 January 2021

Intravitreal triamcinolone injection for treatment of macular edema secondary to branch retinal vein occlusion.

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2009.230

7 January 2021

Intravitreal triamcinolone acetonide in patients with macular oedema due to branch retinal vein occlusion: a pilot study

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2009.230

7 January 2021

Intravitreal triamcinolone for the treatment of ischemic macular edema associated with branch retinal vein occlusion.

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2009.230

7 January 2021

Intravitreal bevacizumab (Avastin) in the treatment of macular edema secondary to branch retinal vein occlusion

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2009.230

7 January 2021

Intravitreal bevacizumab for macular oedema secondary to branch retinal vein occlusion

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2009.230

7 January 2021

Ranibizumab for macular edema due to retinal vein occlusions: implication of VEGF as a critical stimulator.

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2009.230

7 January 2021

Intravitreal triamcinolone for uveitic cystoid macular edema: an optical coherence tomography study.

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2009.230

7 January 2021

Intravitreal triamcinolone for refractory diabetic macular edema

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2009.230

7 January 2021

Intravitreal triamcinolone in the treatment of serous retinal detachment in Vogt-Koyanagi-Harada syndrome.

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2009.230

7 January 2021

Intravitreal triamcinolone acetonide treatment of macular edema associated with central retinal vein occlusion

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2009.230

7 January 2021

In vitro effects of dexamethasone on hypoxia-induced hyperpermeability and expression of vascular endothelial growth factor.

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2009.230

7 January 2021

Intravitreal levels of vascular endothelial growth factor and interleukin-6 are correlated with macular edema in branch retinal vein occlusion

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2009.230

7 January 2021

Clinical, anatomic, and electrophysiologic evaluation following intravitreal bevacizumab for macular edema in retinal vein occlusion

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2009.230

7 January 2021

Intravitreal bevacizumab (Avastin) treatment of macular edema in central retinal vein occlusion: a short-term study

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2009.230

7 January 2021

Intravitreal bevacizumab injections for treatment of central retinal vein occlusion: six-month results of a prospective trial

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2009.230

7 January 2021

Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2009.230

7 January 2021

Primary Intravitreal Bevacizumab (Avastin) for Diabetic Macular Edema

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2009.230

7 January 2021

One-year results after intravitreal bevacizumab therapy for macular edema secondary to branch retinal vein occlusion

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2009.230

7 January 2021

Intravitreal bevacizumab (Avastin) for macular oedema secondary to retinal vein occlusion: 12-month results of a prospective clinical trial

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2009.230

7 January 2021

The lack of toxicity of intravitreally administered triamcinolone acetonide

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2009.230

7 January 2021

Experimental and clinical observations of the intraocular toxicity of commercial corticosteroid preparations

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2009.230

7 January 2021

Evaluation of in vitro effects of bevacizumab (Avastin) on retinal pigment epithelial, neurosensory retinal, and microvascular endothelial cells

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2009.230

7 January 2021

Testing intravitreal toxicity of bevacizumab (Avastin).

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2009.230

7 January 2021

Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab (Avastin).

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2009.230

7 January 2021

Electrophysiologic findings after intravitreal bevacizumab (Avastin) treatment

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2009.230

7 January 2021

Intravitreal triamcinolone as primary treatment of cystoid macular edema secondary to branch retinal vein occlusion

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2009.230

7 January 2021

Secondary ocular hypertension after intravitreal injection of 4 mg of triamcinolone acetonide: incidence and risk factors

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2009.230

7 January 2021

Intravitreal triamcinolone treatment for macular edema associated with central retinal vein occlusion and hemiretinal vein occlusion.

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2009.230

7 January 2021

Conjunctival ulceration following triamcinolone injection

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2009.230

7 January 2021

Short-term complications of intravitreal injections of triamcinolone and bevacizumab

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2009.230

7 January 2021

Infectious and presumed noninfectious endophthalmitis after intravitreal triamcinolone acetonide injection

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2009.230

7 January 2021

Noninfectious endophthalmitis associated with intravitreal triamcinolone injection

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2009.230

7 January 2021

https://api.fatcat.wiki/v0/release/ciu3wubhpbbgjg7ovliv7txpya

Identifiers

1 reference

30 July 2022

mapped directly with Wikidata item

Dimensions Publication ID

1034700153

0 references

Fatcat ID

release_ciu3wubhpbbgjg7ovliv7txpya

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/ciu3wubhpbbgjg7ovliv7txpya

30 July 2022

mapped directly with Wikidata item

https://api.fatcat.wiki/v0/release/ciu3wubhpbbgjg7ovliv7txpya

1 reference

30 July 2022